Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2014
- Source ID
- 10.1016/j.bbmt.2014.06.036
Entities
People
- Andy I. Chen
- Baldeep Wirk
- Bipin N Savani
- César O. Freytes
- David A. Rizzieri
- David G. Maloney
- David I. Marks
- David J. Inwards
- Edward J. Kanfer
- Ernesto Ayala
- Görgün Akpek
- Hillard M Lazarus
- Jeanette Carreras
- Julie M. Vose
- Leona A. Holmberg
- Luciano J. Costa
- Mahmoud Aljurf
- Mark S. Hertzberg
- Mehdi Hamadani
- Melhem Solh
- Nishitha M. Reddy
- Parameswaran N. Hari
- Rammurti T. Kamble
- Richard Olsson
- Siddhartha Ganguly
- Silvia Montoto
- Sonali M Smith
- Taiga Nishihori
- Timothy S. Fenske
- Veronika Bachanova
- Wael Saber
- Yi-Bin Chen
- Ying Zhang
Organizations
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- GSK
- Health Research
- Incyte
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- Terumo BCT (United States)
- Texas Instruments
- University of Minnesota
- University of Utah